Drug Research Division, Dainippon Sumitomo Pharma Co., Ltd, Konohana-ku, Osaka, Japan.
Bioorg Med Chem Lett. 2010 Dec 15;20(24):7246-9. doi: 10.1016/j.bmcl.2010.10.101. Epub 2010 Oct 26.
Structures containing the (R)-3-amino-3-methyl piperidine unit as a new pharmacophore moiety have been shown to possess moderate inhibitory activity for DPP-4 with good pharmacokinetics profile. One of these compounds was found to have good oral bioavailability and PK/PD profile in ZF-rat.
含有(R)-3-氨基-3-甲基哌啶结构单元的新型药效团化合物被证明对 DPP-4 具有中等抑制活性,且具有良好的药代动力学特征。其中一种化合物在 ZF-大鼠中具有良好的口服生物利用度和 PK/PD 特征。